FK506 reduces tissue damage and prevents functional deficit after spinal cord injury in the rat

Journal of Neuroscience Research

Volumn 81, Issue 6, 2005, Pages 827-836

  López Vales, Rubèn ^a   García Alías, Guillermo ^a   Forés, Joaquim ^a,b   Udina, Esther ^a   Gold, Bruce G ^c   Navarro, Xavier ^a   Verdú, Enrique ^a,d  

^a INSTITUT DE NEUROCIÈNCIES   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

FK506; Inflammation; Methylprednisolone; Spinal cord injury; Tissue sparing

Indexed keywords

CYCLOOXYGENASE 2; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 1BETA; LECTIN; METHYLPREDNISOLONE; NITRIC OXIDE SYNTHASE; TACROLIMUS; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; NEUROPROTECTIVE AGENT;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EVOKED MUSCLE RESPONSE; FEMALE; FUNCTIONAL ASSESSMENT; HISTOPATHOLOGY; IMMUNOREACTIVITY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REFLEX; SPINAL CORD INJURY; TISSUE INJURY; TREATMENT OUTCOME; WALKING; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; ELECTROPHYSIOLOGY; GLIOSIS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYCLOOXYGENASE 2; ELECTROPHYSIOLOGY; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOSIS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERLEUKIN-1; METHYLPREDNISOLONE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD INJURIES; TACROLIMUS; WALKING;

EID: 27444436221     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20605     Document Type: Article

References (70)

1. Acarín L, Gonzalez B, Castellano B, Castro AJ. 1997. Quantitative analysis of microglial reaction to a cortical excitotoxic lesion in the early postnatal brain. Exp Neurol 147:410-417.
2. Aschner M. 1998. Astrocytic functions and physiological reaction to injury: the potential to induce and/or exacerbate neuronal dysfunction. A forum position paper. Neurotoxicology 19:7-17.
3. Bao F, Chen Y, Dekaban GA, Weaver LC. 2004. Early anti-inflammatory treatment reduces lipid peroxidation and protein nitration after spinal cord injury in rats. J Neurochem 88:1335-1344.
4. Basso DM, Beattie MS, Bresnahan JC. 1995 A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 12:1-21.
5. Bavetta S, Hamlyn PJ, Burnstock G, Lieberman AR, Anderson PN. 1999. The effects of FK506 on dorsal column axons following spinal cord injury in adult rats: neuroprotection and local regeneration. Exp Neurol 158:382-393.
6. Behrmann DL, Bresnahan JC, Beattie MS. 1994. Modeling of acute spinal cord injury in the rat: neuroprotection and enhanced recovery with methylprednisolone, U-74006F and YM-14673. Exp Neurol 126:61-75.
7. Bethea JR, Dietrich WD. 2002. Targeting the host inflammatory response in traumatic spinal cord injury. Curr Opin Neurol 15:355-360.
8. Blight AR. 2002. Miracles and molecules-progress in spinal cord repair. Nat Neurosci 5:1051-1054.
9. Bracken MB, Holford TR. 2002. Neurological and functional status 1 year after acute spinal cord injury: estimates of functional recovery in National Acute Spinal Cord Injury Study II from results modeled in National Acute Spinal Cord Injury Study III. J Neurosurg 96:259-266.
10. Brecht S, Schwarze K, Waetzig V, Christner C, Heiland S, Fischer G, Sartor K, Herdegen T. 2003. Changes in peptidyl-prolyl cis/trans isomerase activity and FK506 binding protein expression following neuroprotection by FK506 in the ischemic rat brain. Neuroscience 120: 1037-1048.
11. Butcher SP, Henshall DC, Teramura Y, Iwasaki K, Sharkey J. 1997. Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism. J Neurosci 17:6939-6946.
12. Carlson GD, Gorden MD, Nakazawa S, Wada E, Smith JS, Lamanna JC. 2003. Sustained spinal cord compression. Part II: effect of methylprednisolone on regional blood flow and recovery of somatosensory evoked potentials. J Bone Joint Surg 85:95-101.
13. Constantini S, Young W. 1994. The effects of methylprednisolone and the ganglioside GM1 on acute spinal cord injury in rats. J Neurosurg 80: 97-111.
14. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH. 1991. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA 88:6368-6371.
15. Dawson VL, Kizushi VM, Huang PL, Snyder SH, Dawson TM. 1996. Resistance to neurotoxicity in cortical cultures from neuronal nitric oxide synthase-deficient mice. J Neurosci 16:2479-2487.
16. Dawson TM, Steiner JP, Dawson VL, Dinerman JL, Uhl GR, Snyder SH. 1993. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci USA 90:9808-9812.
17. Drake M, Friberg H, Boris-Moller F, Sakata K, Wieloch T. 1996. The immunosuppressant FK506 ameliorates ischaemic damage in the rat brain. Acta Physiol Scand 158:155-159.
18. Dumont RJ, Verma S, Okonkwo DO, Hurlbert RJ, Boulos PT, Ellegala DB, Dumont A. 2001. Acute spinal cord injury, part II: contemporary pharmacotherapy. Clin Neuropharmacol 24:265-279.
19. Fawcett JW, Asher RA. 1999. The glial scar and central nervous system repair. Brain Res Bull 49:377-391.
20. Freeman EE, Grosskreutz CL. 2000. The effects of FK506 on retinal ganglion cells after optic nerve crush. Invest Ophthalmol Vis Sci 41: 1111-1115.
21. Furuichi Y, Katsuta K, Maeda M, Ueyama N, Moriguchi A, Matsuoka N, Goto T, Yanagihara T. 2003. Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy. Brain Res 965: 137-145.
22. Garcia JH, Liu KF, Relton JK. 1995. Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rat with middle cerebral artery occlusion. Am J Pathol 147:1477-1486.
23. García-Alías G, Verdú E, Forés J, López-Vales R, Navarro X. 2003. Functional and electrophysiological characterization of photochemical graded spinal cord injury in the rat. J Neurotrauma 20:501-510.
24. Giordani F, Benetolli A, Favero-Fihlo LA, Lima KCM, Cestari L, Milani H. 2003. Tacrolimus (FK506) reduces ischemia-induced hippocampal damage in rats: a 7- and 30-days study. Braz J Med Biol Res 36:495-502.
25. Gold BG. 2000. Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders. Exp Opinion Invest Drugs 9:2331-2342.
26. Gold BG, Storm-Dickerson T, Austin DR. 1994. The immunosuppressant FK506 increases functional recovery and nerve regeneration following peripheral nerve injury. Restor Neurol Neurosci 6:287-296.
27. Gold BG, Udina E, Bourdette D, Navarro X. 2004a. Neuroregenerative and neuroprotective actions of neuroimmunophilin compounds in traumatic and inflammatory neuropathies. Neurol Res 26:371-380.
28. Gold BG, Villafranca JE. 2003. Neuroimmunophilin ligands: the development of novel neuroregenerative/neuroprotective compounds. Curr Top Med Chem 3:1368-1375.
29. Gold BG, Voda J, Yu X, Gordon H. 2004b. The immunosuppressant FK506 elicits a neuronal heat shock response and protects against acrylamide neuropathy. Exp Neurol 187:160-170.
30. Gold BG, Zhong YP. 2004. FK506 requires stimulation of the extracellular signal regulated kinase 1/2 and the steroid receptor chaperone protein p23 for neurite elongation. Neurosignals 13:122-129.
31. Gris D, Marsh D, Oatway MA, Chen Y, Hamilton EF, Dekaban GA, Weaver LC. 2004. Transient blockade of CD11d/CD18 integrin reduces secondary damage after spinal cord injury, improving sensory, autonomic, and motor function. J Neurosci 24:4043-4051.
32. Haghighi SS, Agrawal SK, Surdell D, Plambeck R, Agrawal S, Johnson GC, Walker A. 2000. Effects of methylprednisolone and MK-801 on functional recovery after experimental chronic spinal cord injury. Spinal Cord 38:733-740.
33. Hains BC, Yucra JA, Hulsebosch CE. 2001. Reduction of pathological and behavioral deficits following spinal cord contusion injury with the selective cyclooxygenase-2 inhibitor NS-398. J Neurotrauma 18:409-423.
34. Huribert RJ. 2000. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg 93:1-7.
35. Klettner A, Herdegen T. 2003. The immunophilin-ligands FK506 and V10, 367 mediate neuroprotection by the heat shock response. Br J Pharmacol 138:1004-1012.
36. López-Vales R, García-Alías G, Forés J, Navarro X, Verdú E. 2004a. Increased expression of cyclo-oxygenase 2 and vascular endothelial growth factor in lesioned spinal cord by transplanted olfactory ensheathing cells. J Neurotrauma 21:1031-1043.
37. López-Vales R, García-Alías G, Forés J, Vela JM, Navarro X, Verdú E. 2004b. Transplanted olfactory ensheathing cells modulate the inflammatory response in the injured spinal cord. Neuron Glia Biol 1:201-209.
38. Madsen JR, MacDonald P, Irwin N, Goldberg DE, Yao GL, Mein KF, Rimm IJ, Stieg PE, Benowitz LI. 1998. Tacrolimus (FK506) increases neuronal expression of GAP-43 and improves functional recovery after spinal cord injury in rats. Exp Neurol 154:673-683.
39. Malmsten J. 1983. Time course of segmental reflex changes after chronic spinal cord hemisection in the rat. Acta Physiol Scand 119:435-443.
40. McTigue DM, Popovich PG, Jakeman LB, Stokes BT. 2002. Strategies for spinal cord injury repair. Prog Brain Res 128:3-8.
41. Mu X, Azbill RD, Springer JE. 2000. Riluzole and methylprednisolone combined treatment improves functional recovery in traumatic spinal cord injury. J Neurotrauma 17:773-780.
42. Navarro X, Valero A, Gudiño G, Forés J, Rodríguez FJ, Verdú E, Pascual R, Cuadras J, Nieto-Sampedro M. 1999. Ensheathing glia transplants promote dorsal root regeneration and spinal reflex restitution after multiple lumbar rhizotomy. Ann Neurol 45:207-215.
43. Oudega M, Vargas CG, Weber AB, Kleitman N, Bunge MB. 1999). Long-term effects of methylprednisolone following transection of adult rat spinal cord. Eur J Neurosci 11:2453-2464.
44. Popovich PG, Guan Z, Wei P, Huitinga I, van RN, Stokes BT. 1999. Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. Exp Neurol 158:351-365.
45. Popovich PG, Hickey WF. 2001. Bone marrow chimeric rats reveal the unique distribution of resident and recruited macrophages in the contused spinal cord. J Neuropathol Exp Neurol 60:676-685.
46. Rabchevsky AG, Fugaccia I, Sullivan PG, Blades DA, Scheff SW. 2002. Efficacy of methylprednisolone therapy for the injured rat spinal cord. J Neurosci Res 68:7-18.
47. Rapalino O, Lazarov-Siegler O, Agranov E, Velan GJ, Yoles E, Fraidakis M, Solomon A, Gepstein R, Katz A, Belkin M, Hadani M, Schwartz M. 1998. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med 4:814-821.
48. Relton JK, Rothwell NJ. 1992. Interleukin-1 receptor antagonist inhibits ischemic and excitotoxic neuronal damage in the rat. Brain Res Bull 29:243-246.
49. Rivlin AS, Tator CH. 1977. Objective clinical assessment of motor function after experimental spinal cord injury in the rat. J Neurosurg 47:577-581.
50. Rosenstiel P, Schramm P, Isenmann S, Brecht S, Eickmeier C, Bürger E, Herdegen T, Sievers J, Lucius R. 2003. Differential effects of immunophilin-ligands (FK506 and V-10, 367) on survival and regeneration of rat retinal ganglion cells in vitro and after optic nerve crush in vivo. J Neurotrauma 20:297-307.
51. Saville LR, Kellian S, MaWhitnney L, Weaver LC, Dekaban GA. 2003. Role of CD11d CD18 integrin in mediating the infiltration of leukocytes into the site of a spinal cord injury. J Neurotrauma 20:1100.
52. Saville LR, Pospisil CH, Mawhinney LA, Bao F, Simedrea FC, Peters AA, O'Connell PJ, Weaver LC, Debakan GA. 2004. A monoclonal antibody to CD11d reduces the inflammatory infiltrate into the injured spinal cord: a potential neuroprotective treatment. J Neuroimmunol 156:42-57.
53. Schreiber SL. 1991. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251:283-287.
54. Schwab M, Bartholdi D. 1996. Degeneration and regeneration of axons in the lesioned spinal cord. Physiol Rev 76:319-370.
55. Shichinohe H, Kuroda S, Abumiya T, Ikeda J, Kobayashi T, Yoshimoto T, Iwasaki Y. 2004. FK506 reduces infarct volume due to permanent focal cerebral ischemia by maintaining BAD turnover and inhibiting cytochrome c release. Brain Res 1001:51-59.
56. Singleton RH, Stone JR, Okonkwo DO, Pelikane AJ, Povlishock JT. 2001. The immunophilin ligand FK506 attenuates axonal injury in an impact-acceleration model of traumatic brain injury. J Neurotrauma 18:607-614.
57. Springer JE, Azbill RD, Nottingham SA, Kennedy SE. 2000. Calcineurin-mediated BAD dephosphorylation activates the caspase-3 apoptotic cascade in traumatic spinal cord injury. J Neurosci 20:7246-7251.
58. Steiner JP, Hamilton GS, Ross DT, Valentine HL, Guo H, Connolly MA, Liang S, Ramsey C, Li JH, Huang W, Howorth P, Soni R, Fuller M, Sauer H, Nowotnik AC, Suzdak PD. 1997. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci USA 94:2019-2024.
59. Stichel CC, Müller HW. 1998. Experimental strategies to promote axonal regeneration after traumatic central nervous system injury. Prog Neurobiol 56:119-148.
60. Sulaiman OA, Voda J, Gold BG, Gordon T. 2002. FK506 increases peripheral nerve regeneration after chronic axotomy but not after chronic Schwann cell denervation. Exp Neurol 175:127-137.
61. Takami T, Oudega M, Bethea JR, Wood PM, Kleitman N, Bunge MB. 2002. Methylprednisolone and interleukin-10 reduce gray matter damage in the contused Fisher rat thoracic spinal cord but do not improve functional outcome. J Neurotrauma 19:653-666.
62. Udina E, Ceballos D, Gold BG, Navarro X. 2003a. FK506 enhances reinnervation by regeneration and by collateral sprouting of peripheral nerve fibers. Exp Neurol 183:220-231.
63. Udina E, Ceballos D, Verdú E, Gold BG, Navarro X. 2002. Bimodal dose-dependence of FK506 on the rate of axonal regeneration in mouse peripheral nerve. Muscle Nerve 26:348-355.
64. Udina E, Voda J, Gold BG, Navarro X. 2003b. Comparative dose-dependence study of FK506 on transected mouse sciatic nerve repaired by allograft or xenograft. J Peripher Nerv Syst 8:145-154.
65. Valero-Cabré A, Forés J, Navarro X. 2004. Reorganization of reflex responses mediated by different afferent sensory fibers after spinal cord transection. J Neurophysiol 91:2838-2848.
66. Verdú E, García-Alías G, Forés J, Vela JM, Cuadras J, López-Vales R, Navarro X. 2003. Morphological characterization of photochemical graded spinal cord injury in the rat. J Neurotrauma 20:483-499.
67. Wang MS, Gold BG. 1999. FK506 increases regeneration of spinal cord axons in a predegenerated peripheral nerve autograft. J Spinal Cord Med 22:287-296.
68. Wang MS, Zeleny-Pooley M, Gold BG. 1997. Comparative dose dependence study of FK506 and cyclosporin A on the rate of axonal regeneration in the rat sciatic nerve. J Pharmacol Exp Ther 282:1084-1097.
69. Winter C, Schenkel J, Bunger E, Eickmeier C, Zimmermann M, Herdegen T. 2000. The immunophilin ligand FK506, but not GPI-1046, protects against neuronal death and inhibits c-Jun expression in the substantia nigra pars compacta following transection of the rat medial forebrain bundle. Neuroscience 95:753-762.
70. Yamasaki Y, Matsuura N, Shozuhara H, Onodera H, Itoyama Y, Kogure K. 1995. Interleukin-1 as a pathogenic mediator of ischemic brain damage in rats. Stroke 26:676-681.